A meta-analysis of 23 studies that included 1438 prostate cancer and 381 adjacent normal samples demonstrated elevated MSH2 expressions in prostate cancer (standardised mean difference = 0.45, 95% CI = 0.26–0.63, p < 0.001) (Figure 4). Here, MSH2 is linked to prostate carcinoma.